Pacific Biosciences of California Inc expected to post a loss of 33 cents a share - Earnings Preview

Pacific Biosciences of California

28/10/2022 14:00

* Pacific Biosciences of California Inc  PACB.OQ 
 PACB.O  is
expected to show a rise in quarterly revenue when it reports 
results on November 7. 
    * The Menlo Park California-based  company is expected to
report 
a 1.5% increase in revenue to $35.4 million from $34.89 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. The company's guidance on August 3
2022, for the period ended September 30, was for revenue between
$35.47 million and $36.18 million.
    * ​Refinitiv's mean analyst estimate for Pacific Biosciences
of
California Inc is for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pacific
Biosciences of California Inc is $10​, above​ its last closing
price of $7.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.32       -0.32      -0.32     Met     1
 Mar. 31 2022  -0.31       -0.31      -0.37     Missed  -20
 Dec. 31 2021  -0.28       -0.28      -0.31     Missed  -9.4​
 Sep. 30 2021  -0.22       -0.22      -0.23     Missed  -5.7
 ​​Jun.        -0.20       -0.21      -0.21     Met     -1.9
 30 2021                                                
 Mar. 31 2021  -0.45       -0.46      -0.45     Beat    1.7​
 Dec. 31 2020  0.30        0.32       0.37      Beat    16.4
 Sep. 30 2020  -0.13       -0.13      -0.14     Missed  -4.5
 This summary was machine generated October 28 at 13:00 GMT.  All
figures in US dollars  unless otherwise stated